ID   BCH869
AC   CVCL_C1MH
SY   BT869; Boston Children's Hospital 869
DR   cancercelllines; CVCL_C1MH
DR   GEO; GSM5434606
DR   GEO; GSM5434607
DR   GEO; GSM5434608
DR   GEO; GSM5434609
DR   GEO; GSM5434610
DR   GEO; GSM5434611
DR   GEO; GSM5434612
DR   GEO; GSM5434613
DR   GEO; GSM5434614
DR   GEO; GSM5434615
DR   GEO; GSM5434616
DR   GEO; GSM5434617
DR   Millipore; SCC218
DR   Wikidata; Q114310689
RX   Patent=US20200384022;
RX   PubMed=29674595;
RX   PubMed=29760046;
CC   Sequence variation: Mutation; HGNC; HGNC:171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Unspecified (PubMed=29674595).
CC   Sequence variation: Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (Patent=US20200384022; PubMed=29674595).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu39Lys (c.115G>A); Zygosity=Unspecified (PubMed=29674595).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Gly1007Arg (c.3019G>C); Zygosity=Unspecified (PubMed=29674595).
CC   Sequence variation: Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Gln510fs (c.1529delA); Zygosity=Unspecified (PubMed=29674595).
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Brainstem, pons; UBERON=UBERON_0000988.
ST   Source(s): Millipore=SCC218
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 12,14
ST   D16S539: 11,13
ST   D18S51: 16,19
ST   D21S11: 30,30.2
ST   D3S1358: 16,18
ST   D5S818: 9,11
ST   D7S820: 10,11
ST   D8S1179: 11,12
ST   FGA: 23,24
ST   Penta D: 12,13
ST   Penta E: 7,12
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C94764; Diffuse intrinsic pontine glioma
DI   ORDO; Orphanet_497188; Diffuse intrinsic pontine glioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   7Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 19-12-24; Version: 7
//
RX   Patent=US20200384022;
RA   Suva M.L., Bernstein B.E., Regev A., Filbin M.G., Tirosh I., Hovestadt V.;
RT   "Methods and compositions for targeting developmental and oncogenic
RT   programs in H3K27M gliomas.";
RL   Patent number US20200384022, 10-Dec-2020.
//
RX   PubMed=29674595; DOI=10.1126/science.aao4750; PMCID=PMC5949869;
RA   Filbin M.G., Tirosh I., Hovestadt V., Shaw M.L., Escalante L.E.,
RA   Mathewson N.D., Neftel C., Frank N., Pelton K., Hebert C.M.,
RA   Haberler C., Yizhak K., Gojo J., Egervari K., Mount C., van Galen P.,
RA   Bonal D.M., Nguyen Q.-D., Beck A., Sinai C., Czech T., Dorfer C.,
RA   Goumnerova L., Lavarino C., Carcaboso A.M., Mora J., Mylvaganam R.,
RA   Luo C.C., Peyrl A., Popovic M., Azizi A.A., Batchelor T.T., Frosch M.P.,
RA   Martinez-Lage M., Kieran M.W., Bandopadhayay P., Beroukhim R.,
RA   Fritsch G., Getz G., Rozenblatt-Rosen O., Wucherpfennig K.W.,
RA   Louis D.N., Monje M., Slavc I., Ligon K.L., Golub T.R., Regev A.,
RA   Bernstein B.E., Suva M.L.;
RT   "Developmental and oncogenic programs in H3K27M gliomas dissected by
RT   single-cell RNA-seq.";
RL   Science 360:331-335(2018).
//
RX   PubMed=29760046; DOI=10.1158/0008-5472.CAN-17-3691; PMCID=PMC6294442;
RA   Pal S., Kozono D., Yang X.-D., Fendler W., Fitts W., Ni J., Alberta J.A.,
RA   Zhao J., Liu K.X., Bian J., Truffaux N., Weiss W.A., Resnick A.C.,
RA   Bandopadhayay P., Ligon K.L., DuBois S.G., Mueller S., Chowdhury D.,
RA   Haas-Kogan D.A.;
RT   "Dual HDAC and PI3K inhibition abrogates NFkappaB- and FOXM1-mediated
RT   DNA damage response to radiosensitize pediatric high-grade gliomas.";
RL   Cancer Res. 78:4007-4021(2018).
//